PARI provides comprehensive analytical services for product development in combination with nebuliser customisation from early phase to submission and commercialisation.

Aerosol Services

We provide comprehensive analytical services for product development in combination with nebulizer optimization from early phase to submission and commercialization.

Experienced scientists design in-vitro aerosol studies according to industry guidance. Together with well-trained staff, they perform studies using state-of-the-art instrumentation and methodologies of the highest analytical quality. This makes it possible to provide our customers with detailed reports for regulatory submission.

With decades of experience in aerosol testing, we provide a broad range of analytical support for non-clinical, pre-clinical, and clinical phases of pharmaceutical product development.

Aerosol characterization of drugs and devices is performed in multiple, specially designed, temperature and humidity controlled lab spaces. These laboratories are fully accredited to the highest quality standards (GMP and ISO 13485).

  • Support for drug-device combination development
  • Device profiling
  • Method development and method qualification
  • Method validation
  • Method transfer
  • Simulated use test
  • Dosing orientation studies
  • Stability studies according to ICH guidelines
  • In-use stability testing
  • Photostability testing
  • In-vitro bioequivalence studies
  • Device cleaning validation
  • Pressurized metered dose inhalation product (pMDI) testing
  • Spacer/valved holding chamber (VHC) testing


We offer customized analytical solutions based on the particular projects' requirements. Methodology is adapted in each case with industry guidelines, pharmacopeias (e.g. Ph. Eur., USP, BP, JP) and customer specifications.

Methods developed and available for different molecules and formulations:

  • Small molecules liquid solutions
  • Protein formulations
  • Peptides
  • Oligonucleotides
  • Suspensions
  • Liposomal formulations


Analytical methods for the determination of:

  • Drug assays and identification
  • Impurities and degradation products
  • Related substances
  • Aerodynamic particle size distribution by cascade impactor (NGI)
  • Droplet size distribution by laser diffraction
  • Total drug substance delivered (using breath simulator or DUSA)
  • Drug substance delivery rate (using breath simulator or constant flow)
  • Drug formulation properties: osmolality, density, viscosity, surface tension
  • Formulation appearance and color

Our expertise also extends to analytics of pressurized metered dose inhalation products (pMDI), along with VHCs with facemasks and dry powder inhalation products (DPI).


Thanks to various models, we are able to simulate various scenarios with different devices and products.

  • Face mask models for spacer/valved holding chamber (VHC) testing
  • Cast models such as the Sophia Anatomical Infant Nose Throat (SAINT) model and Premature Infant Nose Throat (PrINT) model


Our aerosol laboratory is equipped with fully qualified state-of-the-art instrumentation. A wide range of HPLC detectors allows the analysis of a great variety of molecules and formulations. Traditional HPLC methods can be transferred to faster UPLC methods.

  • Next Generation Impactor
  • Unit Dose Sampling Apparatus
  • Breath simulator
  • TSI digital flow meters
  • Automated actuation system for pMDI
  • Ventilation System
eFlow Technology nebulizers with digital therapy management: The PARI Connect eco-system

eFlow Technology nebulizers with digital therapy management

Learn how the PARI Connect system supports patients with carefully considered device usability and digital therapy management solutions.

Read more

Your innovative aerosol therapy – our drug-nebulizer expertise

YOUR innovative aerosol therapy – OUR drug-nebulizer expertise

Watch five short expert interviews containing all you need to know about our partnering approach for pharmaceutical companies.

Read more

Developing new drug-nebulizer combination products

Developing new drug-nebulizer combination products

Learn more about the critical success factors and opportunities for bringing a new vibrating membrane nebulizer as a drug-device combination product to the market.

Read more

Contact us

Do you have any questions about our technology, partnering approach and services?

Please contact us!